Small molecule therapeutics for tauopathy in Alzheimer’s disease: Walking on the path of most resistance

Neuropathological stageing of Alzheimer-related changes.

Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · see citing works

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.

Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676 · see citing works

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668 · see citing works

Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease

Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492 · see citing works

Memantine in Moderate-to-Severe Alzheimer's Disease

Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043 · see citing works

Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models

Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821 · see citing works

Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories

Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656 · see citing works

Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease.

Kosik, K. S., Joachim, C. L., & Selkoe, D. J. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.11.4044 · Cited by 1,462 · see citing works

Tau Mislocalization to Dendritic Spines Mediates Synaptic Dysfunction Independently of Neurodegeneration

Hoover, B. R., Reed, M. N., Su, J., Penrod, R. D., Kotilinek, L. A., Grant, M. K., Pitstick, R., Carlson, G. A., Lanier, L. M., Yuan, L.-L., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.11.030 · Cited by 1,118 · see citing works

Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease

Giannakopoulos, P., Herrmann, F. R., Bussière, T., Bouras, C., Kövari, E., Perl, D. P., Morrison, J. H., Gold, G., & Hof, P. R. (2003) · Neurology · doi:10.1212/01.wnl.0000063311.58879.01 · Cited by 1,118 · see citing works

Tau-targeting therapies for Alzheimer disease

Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · see citing works

Cloning and sequencing of the cDNA encoding an isoform of microtubule‐associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain.

Goedert, M., Spillantini, M. G., Potier, M. C., Ulrich, J., & Crowther, R. A. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb03390.x · Cited by 1,037 · see citing works

Paired Helical Filaments in Electron Microscopy of Alzheimer's Disease

KIDD, M. (1963) · Nature · doi:10.1038/197192b0 · Cited by 1,012 · see citing works

Lithium induces autophagy by inhibiting inositol monophosphatase

Sarkar, S., Floto, R. A., Berger, Z., Imarisio, S., Cordenier, A., Pasco, M., Cook, L. J., & Rubinsztein, D. C. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200504035 · Cited by 985 · see citing works

Current and Future Treatments in Alzheimer Disease: An Update

Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966 · see citing works

Acetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy

Min, S.-W., Cho, S.-H., Zhou, Y., Schroeder, S., Haroutunian, V., Seeley, W. W., Huang, E. J., Shen, Y., Masliah, E., Mukherjee, C., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.044 · Cited by 949 · see citing works

Enhancement of proteasome activity by a small-molecule inhibitor of USP14

Lee, B., Lee, M. J., Park, S., Oh, D., Elsasser, S., Chen, P., Gartner, C. A., Dimova, N. V., Hanna, J. W., Gygi, S. P., et al. (2010) · Nature · doi:10.1038/nature09299 · Cited by 943 · see citing works

Phosphorylation affects the ability of tau protein to promote microtubule assembly.

Lindwall, G., & Cole, R. D. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42989-9 · Cited by 901 · see citing works

Molecular Interplay between Mammalian Target of Rapamycin (mTOR), Amyloid-β, and Tau

Caccamo, A., Majumder, S., Richardson, A., Strong, R., & Oddo, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.100420 · Cited by 881 · see citing works

Ubiquitin Is a Component of Paired Helical Filaments in Alzheimer's Disease

Mori, H., Kondo, J., & Ihara, Y. (1987) · Science · doi:10.1126/science.3029875 · Cited by 843 · see citing works

Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease

Gamblin, T. C., Chen, F., Zambrano, A., Abraha, A., Lagalwar, S., Guillozet, A. L., Lu, M., Fu, Y., Garcia-Sierra, F., LaPointe, N., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1630428100 · Cited by 831 · see citing works

Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: Distinction between PHF-like immunoreactivity and microtubule binding

Biernat, J., Gustke, N., Drewes, G., Mandelkow, E., & Mandelkow, E. (1993) · Neuron · doi:10.1016/0896-6273(93)90279-z · Cited by 796 · see citing works

Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease.

Köpke, E., Tung, Y. C., Shaikh, S., Alonso, A. C., Iqbal, K., & Grundke-Iqbal, I. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80536-5 · Cited by 779 · see citing works

O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer's disease

Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G. W., & Gong, C.-X. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400348101 · Cited by 775 · see citing works

Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation

Liu, F., Grundke‐Iqbal, I., Iqbal, K., & Gong, C. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04391.x · Cited by 759 · see citing works

Peptide sequences that target cytosolic proteins for lysosomal proteolysis

Dice, J. F. (1990) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(90)90019-8 · Cited by 755 · see citing works

CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation

Petrucelli, L. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh083 · Cited by 735 · see citing works

The acetylation of tau inhibits its function and promotes pathological tau aggregation

Cohen, T. J., Guo, J. L., Hurtado, D. E., Kwong, L. K., Mills, I. P., Trojanowski, J. Q., & Lee, V. M. Y. (2011) · Nature Communications · doi:10.1038/ncomms1255 · Cited by 724 · see citing works

The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein

Lu, P.-J., Wulf, G., Zhou, X. Z., Davies, P., & Lu, K. P. (1999) · Nature · doi:10.1038/21650 · Cited by 721 · see citing works

A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo

Yuzwa, S. A., Macauley, M. S., Heinonen, J. E., Shan, X., Dennis, R. J., He, Y., Whitworth, G. E., Stubbs, K. A., McEachern, E. J., Davies, G. J., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.96 · Cited by 717 · see citing works

Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor

Bowers, E. M., Yan, G., Mukherjee, C., Orry, A., Wang, L., Holbert, M. A., Crump, N. T., Hazzalin, C. A., Liszczak, G., Yuan, H., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.03.006 · Cited by 666 · see citing works

Rapamycin alleviates toxicity of different aggregate-prone proteins

Berger, Z., Ravikumar, B., Menzies, F. M., Oroz, L. G., Underwood, B. R., Pangalos, M. N., Schmitt, I., Wullner, U., Evert, B. O., O'Kane, C. J., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddi458 · Cited by 657 · see citing works

From Promiscuity to Precision: Protein Phosphatases Get a Makeover

Virshup, D. M., & Shenolikar, S. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.02.015 · Cited by 643 · see citing works

The high-affinity HSP90–CHIP complex recognizes and selectively degrades phosphorylated tau client proteins

Dickey, C. A., Kamal, A., Lundgren, K., Klosak, N., Bailey, R. M., Dunmore, J., Ash, P., Shoraka, S., Zlatkovic, J., Eckman, C. B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29715 · Cited by 642 · see citing works

Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice

Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Clos, A. L., Jackson, G. R., & Kayed, R. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-39 · Cited by 633 · see citing works

Tau protein kinases: Involvement in Alzheimer's disease

Martin, L., Latypova, X., Wilson, C. M., Magnaudeix, A., Perrin, M.-L., Yardin, C., & Terro, F. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2012.06.003 · Cited by 631 · see citing works

Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing

Wang, Y., Martinez-Vicente, M., Krüger, U., Kaushik, S., Wong, E., Mandelkow, E.-M., Cuervo, A. M., & Mandelkow, E. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp367 · Cited by 617 · see citing works

Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation

Yuzwa, S. A., Shan, X., Macauley, M. S., Clark, T., Skorobogatko, Y., Vosseller, K., & Vocadlo, D. J. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.797 · Cited by 611 · see citing works

Tau and tauopathies

Arendt, T., Stieler, J. T., & Holzer, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.08.018 · Cited by 609 · see citing works

Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2

Neve, R. L., Harris, P. K. W., Kosik, K. S., Kurnit, D. M., & Donlon, T. A. (1986) · Molecular Brain Research · doi:10.1016/0169-328x(86)90033-1 · Cited by 565 · see citing works

Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.

Wischik, C. M., Edwards, P. C., Lai, R. Y., Roth, M., & Harrington, C. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.11213 · Cited by 547 · see citing works

Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology

Rissman, R. A., Poon, W. W., Blurton-Jones, M., Oddo, S., Torp, R., Vitek, M. P., LaFerla, F. M., Rohn, T. T., & Cotman, C. W. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420640 · Cited by 543 · see citing works

Inhibition of Heparin-induced Tau Filament Formation by Phenothiazines, Polyphenols, and Porphyrins

Taniguchi, S., Suzuki, N., Masuda, M., Hisanaga, S., Iwatsubo, T., Goedert, M., & Hasegawa, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408714200 · Cited by 540 · see citing works

A Phase II Trial of Tideglusib in Alzheimer's Disease

Lovestone, S., for the ARGO investigators, Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., Calero, M., Andrés, M. V., Gómez-Carrillo, B., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141959 · Cited by 536 · see citing works

Neuroprotective effects of curcumin

Cole, G. M., Teter, B., & Frautschy, S. A. (2007) · ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY · doi:10.1007/978-0-387-46401-5_8 · Cited by 516 · see citing works

Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits

Min, S.-W., Chen, X., Tracy, T. E., Li, Y., Zhou, Y., Wang, C., Shirakawa, K., Minami, S. S., Defensor, E., Mok, S. A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3951 · Cited by 516 · see citing works

Neocortical Neurofibrillary Tangles Correlate With Dementia Severity in Alzheimer's Disease

Bierer, L. M., Hof, P. R., Purohit, D. P., Carlin, L., Schmeidler, J., Davis, K. L., & Perl, D. P. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540250089017 · Cited by 514 · see citing works

Proteasome inhibition by paired helical filament‐tau in brains of patients with Alzheimer's disease

Keck, S., Nitsch, R., Grune, T., & Ullrich, O. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01642.x · Cited by 483 · see citing works

CHIP-Hsc70 Complex Ubiquitinates Phosphorylated Tau and Enhances Cell Survival

Shimura, H., Schwartz, D., Gygi, S. P., & Kosik, K. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m305838200 · Cited by 469 · see citing works

Multiple-motor based transport and its regulation by Tau

Vershinin, M., Carter, B. C., Razafsky, D. S., King, S. J., & Gross, S. P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607919104 · Cited by 457 · see citing works

Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling

Myeku, N., Clelland, C. L., Emrani, S., Kukushkin, N. V., Yu, W. H., Goldberg, A. L., & Duff, K. E. (2016) · Nature Medicine · doi:10.1038/nm.4011 · Cited by 446 · see citing works

Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease

Liu, F., Shi, J., Tanimukai, H., Gu, J., Gu, J., Grundke-Iqbal, I., Iqbal, K., & Gong, C.-X. (2009) · Brain · doi:10.1093/brain/awp099 · Cited by 439 · see citing works

Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling

Kickstein, E., Krauß, S., Thornhill, P., Rutschow, D., Zeller, R., Sharkey, J., Williamson, R., Fuchs, M., Köhler, A., Glossmann, H. H., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912793107 · Cited by 432 · see citing works

Advanced Glycation End Products in Alzheimer's Disease and Other Neurodegenerative Diseases

Sasaki, N., Fukatsu, R., Tsuzuki, K., Hayashi, Y., Yoshida, T., Fujii, N., Koike, T., WAKAYAMA, I., Yanagihara, R. T., Garruto, R. M., et al. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65659-3 · Cited by 411 · see citing works

Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial

Forlenza, O. V., Diniz, B. S., Radanovic, M., Santos, F. S., Talib, L. L., & Gattaz, W. F. (2011) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.110.080044 · Cited by 407 · see citing works

Inducing Autophagy by Rapamycin Before, but Not After, the Formation of Plaques and Tangles Ameliorates Cognitive Deficits

Majumder, S., Richardson, A. G., Strong, R., & Oddo, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025416 · Cited by 401 · see citing works

Xylulose 5-phosphate mediates glucose-induced lipogenesis by xylulose 5-phosphate-activated protein phosphatase in rat liver

Kabashima, T., Kawaguchi, T., Wadzinski, B. E., & Uyeda, K. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0730817100 · Cited by 401 · see citing works

Protein phosphatase 2A: a target for anticancer therapy

Perrotti, D., & Neviani, P. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70558-2 · Cited by 400 · see citing works

Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety

Burgin, A. B., Magnússon, Ó. Þ., Singh, J., Witte, P., Staker, B. L., Björnsson, J. M., Þorsteinsdóttir, M., Hrafnsdóttir, S., Hagen, T. J., Kiselyov, A. S., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1598 · Cited by 396 · see citing works

PP2A holoenzyme assembly: In cauda venenum (the sting is in the tail)

Janssens, V., Longin, S., & Goris, J. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.12.004 · Cited by 390 · see citing works

Astrocytes are important mediators of Aβ-induced neurotoxicity and tau phosphorylation in primary culture

Garwood, C. J., Pooler, A. M., Atherton, J., Hanger, D. P., & Noble, W. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.50 · Cited by 379 · see citing works

O-GlcNAcase Uses Substrate-assisted Catalysis

Macauley, M. S., Whitworth, G. E., Debowski, A. W., Chin, D., & Vocadlo, D. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413819200 · Cited by 378 · see citing works

Tau aggregation is driven by a transition from random coil to beta sheet structure.

von Bergen, M., Barghorn, S., Biernat, J., Mandelkow, E., & Mandelkow, E. (2005) · Biochimica et Biophysica Acta · doi:10.1016/j.bbadis.2004.09.010 · Cited by 376 · see citing works

Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder

Nunes, P. V., Forlenza, O. V., & Gattaz, W. F. (2007) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.106.029868 · Cited by 369 · see citing works

<scp>mTOR</scp> regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies

Caccamo, A., Magrì, A., Medina, D. X., Wisely, E. V., López‐Aranda, M. F., Silva, A. J., & Oddo, S. (2013) · Aging Cell · doi:10.1111/acel.12057 · Cited by 362 · see citing works

Glycosylation of microtubule–associated protein tau: An abnormal posttranslational modification in Alzheimer's disease

Wang, J.-Z., Grundke-Iqbal, I., & Iqbal, K. (1996) · Nature Medicine · doi:10.1038/nm0896-871 · Cited by 360 · see citing works

Straight and paired helical filaments in Alzheimer disease have a common structural unit.

Crowther, R. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.6.2288 · Cited by 354 · see citing works

Tau and neuroinflammation: what impact for Alzheimer's disease and tauopathies?

Laurent, C., Buée, L., & Blum, D. (2018) · Biomedical Journal · doi:10.1016/j.bj.2018.01.003 · Cited by 348 · see citing works

Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy

Schaeffer, V., Lavenir, I., Ozcelik, S., Tolnay, M., Winkler, D. T., & Goedert, M. (2012) · Brain · doi:10.1093/brain/aws143 · Cited by 343 · see citing works

Treatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study

del Ser, T., Steinwachs, K. C., Gertz, H. J., Andrés, M. V., Gómez-Carrillo, B., Medina, M., Vericat, J. A., Redondo, P., Fleet, D., & León, T. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120805 · Cited by 329 · see citing works

Accelerated neurodegeneration through chaperone-mediated oligomerization of tau

Blair, L. J., Nordhues, B. A., Hill, S. E., Scaglione, K. M., O’Leary, J. C., Fontaine, S. N., Breydo, L., Zhang, B., Li, P., Wang, L., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69003 · Cited by 322 · see citing works

Chaperone-mediated autophagy in aging and disease

Massey, A. C., Zhang, C., & Cuervo, A. M. (2006) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(05)73007-6 · Cited by 315 · see citing works

Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage

Shafiei, S. S., Guerrero-Muñoz, M. J., & Castillo-Carranza, D. L. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00083 · Cited by 314 · see citing works

Alzheimer Disease-specific Conformation of Hyperphosphorylated Paired Helical Filament-Tau Is Polyubiquitinated through Lys-48, Lys-11, and Lys-6 Ubiquitin Conjugation

Cripps, D., Thomas, S. N., Jeng, Y., Yang, F., Davies, P., & Yang, A. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512786200 · Cited by 312 · see citing works

Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway

Lu, M., Liu, T., Jiao, Q., Ji, J., Tao, M., Liu, Y., You, Q., & Jiang, Z. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.01.063 · Cited by 310 · see citing works

Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance

Cook, C. N., Carlomagno, Y., Gendron, T. F., Dunmore, J. H., Scheffel, K., Stetler, C. T., Davis, M., Dickson, D. W., Jarpe, M. B., Deture, M. A., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt402 · Cited by 309 · see citing works

Current and future treatments in Alzheimer’s disease

Atri, A. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1678581 · Cited by 309 · see citing works

Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.

Hampel, H. J., Ewers, M., Bürger, K., Annas, P., Mörtberg, A., Bogstedt, A., Frölich, L., Schröder, J., Schönknecht, P., Riepe, M. W., et al. (2009) · PubMed · Cited by 305 · see citing works

Current Advances on Different Kinases Involved in Tau Phosphorylation, and Implications in Alzheimers Disease and Tauopathies

Ferrer, I., Gómez‐Isla, T., Puig, B., Freixes, M., Ribé, E. M., Dalfó, E., & Ávila, J. (2005) · Current Alzheimer Research · doi:10.2174/1567205052772713 · Cited by 302 · see citing works

Increased levels of granular tau oligomers: An early sign of brain aging and Alzheimer's disease

Maeda, S., Sahara, N., Saito, Y., Murayama, S., Ikai, A., & Takashima, A. (2006) · Neuroscience Research · doi:10.1016/j.neures.2005.11.009 · Cited by 301 · see citing works

Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation

Rodríguez-Navarro, J. A., Rodríguez, L., Casarejos, M. J., Solano, R. M., Gómez, A., Perucho, J., Cuervo, A. M., García de Yébenes, J., & Mena, M. A. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.05.014 · Cited by 298 · see citing works

Autophagic degradation of tau in primary neurons and its enhancement by trehalose

Krüger, U., Wang, Y., Kumar, S., & Mandelkow, E.-M. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.11.009 · Cited by 297 · see citing works

Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo

Congdon, E. E., Wu, J. W., Myeku, N., Figueroa, Y. H., Herman, M., Marinec, P. S., Gestwicki, J. E., Dickey, C. A., Yu, W. H., & Duff, K. E. (2012) · Autophagy · doi:10.4161/auto.19048 · Cited by 297 · see citing works

Lithium Trial in Alzheimer's Disease

Hampel, H. J., Ewers, M., Bürger, K., Annas, P., Mörtberg, A., Bogstedt, A., Frölich, L., Schröder, J., Schönknecht, P., Riepe, M. W., et al. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04606 · Cited by 297 · see citing works

Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer’s disease models

van Eersel, J., Ke, Y. D., Liu, X., Delerue, F., Kril, J. J., Götz, J., & Ittner, L. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009038107 · Cited by 284 · see citing works

Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models

Silva, M. C., Ferguson, F. M., Cai, Q., Donovan, K. A., Nandi, G., Patnaik, D., Zhang, T., Huang, H.-T., Lucente, D. E., Dickerson, B. C., et al. (2019) · eLife · doi:10.7554/elife.45457 · Cited by 283 · see citing works

Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies

Luo, W., Dou, F., Rodina, A., Chip, S., Kim, J., Zhao, Q., Moulick, K., Aguirre, J., Wu, N. F., Greengard, P., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701055104 · Cited by 274 · see citing works

Tau Aggregation Inhibitor Therapy: An Exploratory Phase 2 Study in Mild or Moderate Alzheimer's Disease

Wischik, C. M., Staff, R. T., Wischik, D. J., Bentham, P., Murray, A. D., Storey, J. M. D., Kook, K. A., & Harrington, C. R. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142874 · Cited by 269 · see citing works

Lithium Treatment and Risk of Dementia

Kessing, L. V., Søndergård, L., Forman, J. L., & Andersen, P. K. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.11.1331 · Cited by 267 · see citing works

Proline Isomer-Specific Antibodies Reveal the Early Pathogenic Tau Conformation in Alzheimer's Disease

Nakamura, K., Greenwood, A., Binder, L. I., Bigio, E. H., Denial, S., Nicholson, L. K., Zhou, X. Z., & Lu, K. P. (2012) · Cell · doi:10.1016/j.cell.2012.02.016 · Cited by 255 · see citing works

NAG-thiazoline, An N-Acetyl-β-hexosaminidase Inhibitor That Implicates Acetamido Participation

Knapp, S., Vocadlo, D. J., Gao, Z., Kirk, B. A., Lou, J., & Withers, S. G. (1996) · Journal of the American Chemical Society · doi:10.1021/ja960826u · Cited by 248 · see citing works

Deletion of the Ubiquitin Ligase CHIP Leads to the Accumulation, But Not the Aggregation, of Both Endogenous Phospho- and Caspase-3-Cleaved Tau Species

Dickey, C. A., Yue, M., Lin, W.-L., Dickson, D. W., Dunmore, J. H., Lee, W. C., Zehr, C., West, G., Cao, S., Clark, A. M. K., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0746-06.2006 · Cited by 248 · see citing works

Specific Knockdown of Endogenous Tau Protein by Peptide-Directed Ubiquitin-Proteasome Degradation

Chu, T.-T., Gao, N., Li, Q.-Q., Chen, P.-G., Yang, X.-F., Chen, Y.-X., Zhao, Y.-F., & Li, Y.-M. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.02.016 · Cited by 247 · see citing works

Selective inhibitors of the FK506-binding protein 51 by induced fit

Gaali, S., Kirschner, A., Cuboni, S., Hartmann, J., Kozany, C., Balsevich, G., Namendorf, C., Fernandez-Vizarra, P., Sippel, C., Zannas, A. S., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1699 · Cited by 245 · see citing works

Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells

Usenovic, M., Niroomand, S., Drolet, R. E., Yao, L., Gaspar, R. C., Hatcher, N. G., Schachter, J., Renger, J. J., & Parmentier-Batteur, S. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.1523-15.2015 · Cited by 245 · see citing works

Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors

Wachtel, H. (1983) · Neuropharmacology · doi:10.1016/0028-3908(83)90239-3 · Cited by 242 · see citing works

Are NSAIDs useful to treat Alzheimer’s disease or mild cognitive impairment?

Imbimbo, B. P. (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00019 · Cited by 240 · see citing works

Trimming of Ubiquitin Chains by Proteasome-associated Deubiquitinating Enzymes

Lee, M. J., Lee, B., Hanna, J. W., King, R. W., & Finley, D. J. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r110.003871 · Cited by 239 · see citing works

SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination

Luo, H.-B., Xia, Y.-Y., Shu, X.-J., Liu, Z.-C., Feng, Y., Liu, X.-H., Yu, G., Yin, G., Xiong, Y.-S., Zeng, K., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417548111 · Cited by 236 · see citing works

Chemical Manipulation of Hsp70 ATPase Activity Regulates Tau Stability

Jinwal, U. K., Miyata, Y., Koren, J., Jones, J. R., Trotter, J. H., Chang, L., O’Leary, J. C., Morgan, D., Lee, D. C., Shults, C. L., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.3345-09.2009 · Cited by 231 · see citing works

PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery

Gu, S., Cui, D., Chen, X., Xiong, X., & Zhao, Y. (2018) · BioEssays · doi:10.1002/bies.201700247 · Cited by 231 · see citing works

Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease

Maqbool, M., Mobashir, M., & Hoda, N. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.10.018 · Cited by 228 · see citing works

Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice.

Ozcelik, S., Fraser, G., Castets, P., Schaeffer, V., Skachokova, Z., Breu, K., Clavaguera, F., Sinnreich, M., Kappos, L., Goedert, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062459 · Cited by 226 · see citing works

cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins

Lokireddy, S., Kukushkin, N. V., & Goldberg, A. L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522332112 · Cited by 222 · see citing works

Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease.

Chesser, A. S., Pritchard, S. M., & Johnson, G. V. W. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00122 · Cited by 219 · see citing works

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

Wilcock, G. K., Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170560 · Cited by 219 · see citing works

Does lithium protect against dementia?

Kessing, L. V., Forman, J. L., & Andersen, P. K. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00788.x · Cited by 215 · see citing works

The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules

Jinwal, U. K., Koren, J., Borysov, S. I., Schmid, A. B., Abisambra, J. F., Blair, L. J., Johnson, A. G., Jones, J. R., Shults, C. L., O'Leary, J. C., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4815-09.2010 · Cited by 214 · see citing works

Association of Lithium in Drinking Water With the Incidence of Dementia

Kessing, L. V., Gerds, T. A., Knudsen, N. N., Jørgensen, L. F., Kristiansen, S. M., Voutchkova, D., Ernstsen, V., Schullehner, J., Hansen, B., Andersen, P. K., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2362 · Cited by 213 · see citing works

Curcumin Suppresses Soluble Tau Dimers and Corrects Molecular Chaperone, Synaptic, and Behavioral Deficits in Aged Human Tau Transgenic Mice

Ma, Q., Zuo, X., Yang, F., Ubeda, O. J., Gant, D. J., Alaverdyan, M., Teng, E., Hu, S., Chen, P., Maiti, P., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.393751 · Cited by 212 · see citing works

Proapoptotic Effects of Tau Cleavage Product Generated by Caspase-3

Chung, C.-W., Song, Y.-H., Kim, I.-K., Yoon, W. J., Ryu, B. R., Jo, D., Woo, H., Kwon, Y.-K., Kim, H., Gwag, B.-J., et al. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0335 · Cited by 211 · see citing works

Loss of <i>O</i> -GlcNAc glycosylation in forebrain excitatory neurons induces neurodegeneration

Wang, A. C., Jensen, E. H., Rexach, J. E., Vinters, H. V., & Hsieh-Wilson, L. C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606899113 · Cited by 211 · see citing works

Towards a Pharmacophore for Amyloid

Landau, M., Sawaya, M. R., Faull, K. F., Laganowsky, A. D., Jiang, L., Sievers, S. A., Liu, J., Barrio, J. R., & Eisenberg, D. S. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1001080 · Cited by 209 · see citing works

The expression and distribution of the microtubule-associated proteins tau and microtubule-associated protein 2 in hippocampal neurons in the rat in situ and in cell culture

Dotti, C. G., Banker, G., & Binder, L. (1987) · Neuroscience · doi:10.1016/0306-4522(87)90276-4 · Cited by 199 · see citing works

Lithium as a Treatment for Alzheimer’s Disease: A Systematic Review and Meta-Analysis

Matsunaga, S., Kishi, T., Annas, P., Basun, H., Hampel, H. J., & Iwata, N. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150437 · Cited by 196 · see citing works

It’s all about tau

Tapia‐Rojas, C., Cabezas-Opazo, F., Deaton, C. A., Vergara, E. H., Johnson, G. V. W., & Quintanilla, R. A. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.005 · Cited by 195 · see citing works

Downregulation of Protein Phosphatase 2A Carboxyl Methylation and Methyltransferase May Contribute to Alzheimer Disease Pathogenesis

Sontag, E., Hladik, C. L., Montgomery, L. G., Luangpirom, A., Mudrak, I., Ogris, E., & White, C. L. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.10.1080 · Cited by 191 · see citing works

Characterization of Celastrol to Inhibit Hsp90 and Cdc37 Interaction*

Zhang, T., Li, Y.-Y., Yu, Y.-K., Zou, P., Jiang, Y.-Q., & Sun, D.-X. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.051532 · Cited by 189 · see citing works

Enhanced Phosphatase Activity Attenuates α-Synucleinopathy in a Mouse Model

Lee, K.-W., Chen, W. W., Junn, E., Im, J., Grosso, H., Sonsalla, P. K., Feng, X., Ray, N., Fernandez, J. R., Chao, Y., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.6513-10.2011 · Cited by 184 · see citing works

Microdose Lithium Treatment Stabilized Cognitive Impairment in Patients with Alzheimer’s Disease

Nunes, M. A., Viel, T. A., & Buck, H. S. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310010014 · Cited by 183 · see citing works

Specific Targeting of Tau Oligomers in Htau Mice Prevents Cognitive Impairment and Tau Toxicity Following Injection with Brain-Derived Tau Oligomeric Seeds

Castillo‐Carranza, D. L., Gerson, J. E., Sengupta, U., Guerrero‐Munoz, M. J., Lasagna‐Reeves, C. A., & Kayed, R. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132477 · Cited by 180 · see citing works

Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden

O’Leary, J. C., Li, Q., Marinec, P. S., Blair, L. J., Congdon, E. E., Johnson, A. G., Jinwal, U. K., Koren, J., Jones, J. R., Kraft, C., et al. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-45 · Cited by 176 · see citing works

The Cochaperone BAG2 Sweeps Paired Helical Filament- Insoluble Tau from the Microtubule

Carrettiero, D. C., Hernández, I., Neveu, P. A., Papagiannakopoulos, T. Y., & Kosik, K. S. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.4660-08.2009 · Cited by 175 · see citing works

Sequence and Structure Classification of Kinases

Cheek, S., Zhang, H., & Grishin, N. V. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00538-7 · Cited by 174 · see citing works

Curcumin‐Derived Pyrazoles and Isoxazoles: Swiss Army Knives or Blunt Tools for Alzheimer's Disease?

Narlawar, R., Pickhardt, M., Leuchtenberger, S., Baumann, K., Krause, S., Dyrks, T., Weggen, S., Mandelkow�, E., & Schmidt, B. (2007) · ChemMedChem · doi:10.1002/cmdc.200700218 · Cited by 174 · see citing works

Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia

DeRemer, D. L., Ustun, C., & Natarajan, K. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.11.014 · Cited by 172 · see citing works

Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial

Forlenza, O. V., Radanovic, M., Talib, L. L., & Gattaz, W. F. (2019) · British Journal of Psychiatry · doi:10.1192/bjp.2019.76 · Cited by 171 · see citing works

Protein-Capped Metal Nanoparticles Inhibit Tau Aggregation in Alzheimer’s Disease

Sonawane, S. K., Ahmad, A., & Chinnathambi, S. (2019) · ACS Omega · doi:10.1021/acsomega.9b01411 · Cited by 166 · see citing works

A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease

Nygaard, H. B., Wagner, A. F., Bowen, G. S., Good, S. P., MacAvoy, M. G., Strittmatter, K. A., Kaufman, A. C., Rosenberg, B. J., Sekine-Konno, T., Varma, P., et al. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0119-0 · Cited by 164 · see citing works

Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice

Hastings, N. B., Wang, X., Song, L., Butts, B. D., Grotz, D., Hargreaves, R., Fred Hess, J., Hong, K.-L. K., Huang, C. R.-R., Hyde, L., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0181-0 · Cited by 164 · see citing works

Targeting Fyn Kinase in Alzheimer’s Disease

Nygaard, H. B. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.06.004 · Cited by 162 · see citing works

HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites

Dickey, C. A., Dunmore, J., Lu, B., Wang, J., Lee, W. C., Kamal, A., Burrows, F., Eckman, C., Hutton, M., & Petrucelli, L. (2006) · The FASEB Journal · doi:10.1096/fj.05-5343fje · Cited by 160 · see citing works

Rhodanine‐Based Tau Aggregation Inhibitors in Cell Models of Tauopathy

Bulic, B., Pickhardt, M., Khlistunova, I., Biernat, J., Mandelkow, E., Mandelkow�, E., & Waldmann, H. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200704051 · Cited by 158 · see citing works

N‐Acetylgucosaminono‐1,5‐lactone oxime and the corresponding (phenylcarbamoyl)oxime

Horsch, M., Hoesch, L., Vasella, A. T., & Rast, D. M. (1991) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1991.tb15976.x · Cited by 156 · see citing works

The history of Z-VAD-FMK, a tool for understanding the significance of caspase inhibition

Noorden, C. J. F. V. (2001) · Acta Histochemica · doi:10.1078/0065-1281-00601 · Cited by 152 · see citing works

An inhibitor of the proteasomal deubiquitinating enzyme USP14 induces tau elimination in cultured neurons

Boselli, M. G., Lee, B., Robert, J., Prado, M. A., Min, S., Cheng, C., Silva, M. C., Seong, C., Elsasser, S., Hatle, K. M., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.815126 · Cited by 151 · see citing works

Broad-spectrum caspase inhibitors: from myth to reality?

Chauvier, D., Ankri, S., Charriaut‐Marlangue, C., Casimir, R., & Jacotot, E. D. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402044 · Cited by 150 · see citing works

SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy

Min, S., Sohn, P., Li, Y., Devidze, N., Johnson, J. R., Krogan, N. J., Masliah, E., Mok, S., Gestwicki, J. E., & Gan, L. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.2369-17.2018 · Cited by 148 · see citing works

Why Pleiotropic Interventions are Needed for Alzheimer's Disease

Frautschy, S. A., & Cole, G. M. (2010) · Molecular Neurobiology · doi:10.1007/s12035-010-8137-1 · Cited by 147 · see citing works

Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease

van Dyck, C. H., Nygaard, H. B., Chen, K., Donohue, M., Raman, R., Rissman, R. A., Brewer, J. B., Koeppe, R. A., Chow, T. W., Rafii, M. S., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2050 · Cited by 144 · see citing works

Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies

Selnick, H. G., Hess, J. F., Tang, C., Liu, K., Schachter, J. B., Ballard, J. E., Marcus, J., Klein, D. J., Wang, X., Pearson, M. S., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01090 · Cited by 144 · see citing works

Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation

Crowe, A., James, M. J., Lee, V. M.-Y., Smith, A. B., Trojanowski, J. Q., Ballatore, C., & Brunden, K. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.436006 · Cited by 143 · see citing works

An acetylation–phosphorylation switch that regulates tau aggregation propensity and function

Carlomagno, Y., Chung, D.-E. C., Yue, M., Castanedes-Casey, M., Madden, B. J., Dunmore, J., Tong, J., DeTure, M., Dickson, D. W., Petrucelli, L., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.794602 · Cited by 143 · see citing works

High-throughput screen for small molecules that modulate the ATPase activity of the molecular chaperone DnaK

Chang, L., Bertelsen, E. B., Wisén, S., Larsen, E. M., Zuiderweg, E. R. P., & Gestwicki, J. E. (2007) · Analytical Biochemistry · doi:10.1016/j.ab.2007.08.020 · Cited by 142 · see citing works

The structural requirements for ceramide activation of serine-threonine protein phosphatases

Chalfant, C. E., Szulc, Z. M., Roddy, P. L., Bielawska, A. E., & Hannun, Y. A. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m300347-jlr200 · Cited by 141 · see citing works

Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease

Mena, R., Edwards, P. C., Harrington, C. R., Mukaetova‐Ladinska, E. B., & Wischik, C. M. (1996) · Acta Neuropathologica · doi:10.1007/s004010050477 · Cited by 137 · see citing works

Does Lithium Protect Against Dementia

Dubovsky, S. L. (2008) · Journal watch · doi:10.1056/jp200812220000002 · Cited by 137 · see citing works

Synthesis and Initial Evaluation of YM-08, a Blood-Brain Barrier Permeable Derivative of the Heat Shock Protein 70 (Hsp70) Inhibitor MKT-077, Which Reduces Tau Levels

Miyata, Y., Li, X., Lee, H.-F., Jinwal, U. K., Srinivasan, S. R., Seguin, S. P., Young, Z. T., Brodsky, J. L., Dickey, C. A., Sun, D., et al. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn300210g · Cited by 135 · see citing works

Quantitative Decrease in Synaptophysin Message Expression and Increase in Cathepsin D Message Expression in Alzheimer Disease Neurons Containing Neurofibrillary Tangles

Callahan, L. M., Vaules, W. A., & Coleman, P. D. (1999) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199903000-00007 · Cited by 129 · see citing works

Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy

Graham, D. L., Gray, A. J., Joyce, J. A., Yu, D., O’Moore, J., Carlson, G. A., Shearman, M. S., Dellovade, T., & Hering, H. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.11.025 · Cited by 129 · see citing works

Hsp90 activator Aha1 drives production of pathological tau aggregates

Shelton, L. B., Baker, J. D., Zheng, D., Sullivan, L. E., Solanki, P. K., Webster, J. M., Sun, Z., Sabbagh, J. J., Nordhues, B. A., Koren, J., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707039114 · Cited by 128 · see citing works

Carnosic acid modulates Akt/IKK/NF-κB signaling by PP2A and induces intrinsic and extrinsic pathway mediated apoptosis in human prostate carcinoma PC-3 cells

Kar, S., Palit, S., Ball, W. B., & Das, P. K. (2012) · APOPTOSIS · doi:10.1007/s10495-012-0715-4 · Cited by 127 · see citing works

Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer’s Disease

Turner, R. S., Hebron, M. L., Lawler, A., Mundel, E. E., Yusuf, N., Starr, J. N., Anjum, M., Pagan, F., Torres‐Yaghi, Y., Shi, W., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25775 · Cited by 126 · see citing works

Apolipoprotein E and Peptide Mimetics Modulate Inflammation by Binding the SET Protein and Activating Protein Phosphatase 2A

Christensen, D. J., Ohkubo, N., Oddo, J., Van Kanegan, M. J., Neil, J., Li, F., Colton, C. A., & Vitek, M. P. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002847 · Cited by 125 · see citing works

Versatility of the Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3β Inhibitors

Martino, R. M. C. D., Simone, A. D., Andrisano, V., Bisignano, P., Bisi, A., Gobbi, S., Rampa, A., Fato, R., Bergamini, C., Pérez, D. I., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00894 · Cited by 124 · see citing works

Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease

Noble, W., Garwood, C., Stephenson, J., Kinsey, A. M., Hanger, D., & Anderton, B. (2009) · The FASEB Journal · doi:10.1096/fj.08-113795 · Cited by 123 · see citing works

Dual modification of Alzheimer’s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach

Thomas, S. N., Funk, K. E., Wan, Y., Liao, Z., Davies, P., Kuret, J., & Yang, A. J. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0893-0 · Cited by 123 · see citing works

Acetylation changes tau interactome to degrade tau in Alzheimer’s disease animal and organoid models

Choi, H., Kim, H. J., Yang, J., Chae, S., Lee, W., Chung, S., Kim, J., Choi, H., Song, H., Lee, C. K., et al. (2019) · Aging Cell · doi:10.1111/acel.13081 · Cited by 122 · see citing works

Involvement of in the abnormal hyperphosphorylation of tau and its reversal by Memantine

Chohan, M. O., Khatoon, S., Iqbal, I.-G., & Iqbal, K. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.06.021 · Cited by 120 · see citing works

Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance

Jiang, T., Yu, J., Zhu, X., Zhang, Q.-Q., Cao, L., Wang, H.-F., Tan, M., Gao, Q., Qin, H., Zhang, Y., et al. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.05.032 · Cited by 118 · see citing works

Differential Effects of an O-GlcNAcase Inhibitor on Tau Phosphorylation

Yu, Y., Zhang, L., Li, X., Run, X., Liang, Z., Li, Y., Liu, Y., Lee, M. H., Grundke, I., Iqbal, K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035277 · Cited by 113 · see citing works

Interaction of Cinnamaldehyde and Epicatechin with Tau: Implications of Beneficial Effects in Modulating Alzheimer's Disease Pathogenesis

George, R. C., Lew, J., & Graves, D. J. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122113 · Cited by 112 · see citing works

Therapeutic strategies for the treatment of tauopathies: Hopes and challenges

Khanna, M. R., Kovalevich, J., Lee, V. M. ‐., Trojanowski, J. Q., & Brunden, K. R. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.006 · Cited by 112 · see citing works

Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer's Disease

Cardoso, B. R., Roberts, B. R., Malpas, C. B., Vivash, L. E., Genc, S., Saling, M. M., Desmond, P. M., Steward, C. E., Hicks, R. J., Callahan, J., et al. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0662-z · Cited by 110 · see citing works

Allosteric Heat Shock Protein 70 Inhibitors Rapidly Rescue Synaptic Plasticity Deficits by Reducing Aberrant Tau

Abisambra, J. F., Jinwal, U. K., Miyata, Y., Rogers, J. T., Blair, L. J., Li, X., Seguin, S. P., Wang, L., Jin, Y. L., Bacon, J. A., et al. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.02.027 · Cited by 109 · see citing works

Ligand-Dependent Inhibition and Reversal of Tau Filament Formation

Chirita, C. N., Necula, M., & Kuret, J. (2004) · Biochemistry · doi:10.1021/bi036094h · Cited by 104 · see citing works

A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer’s Disease Mice

Cuadrado‐Tejedor, M., García, C., Sánchez-Arias, J. A., Rabal, O., Pérez-González, M., Mederos, S., Ugarte, A., Franco, R., Segura, V., Perea, G., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.163 · Cited by 104 · see citing works

Cleavage of Tau by calpain in Alzheimer's disease: the quest for the toxic 17 kD fragment

Garg, S., Timm, T., Mandelkow, E.-M., Mandelkow, E., & Wang, Y. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.09.008 · Cited by 103 · see citing works

Small Molecule Enhancement of 20S Proteasome Activity Targets Intrinsically Disordered Proteins

Jones, C. L., Njomen, E., Sjögren, B., Dexheimer, T. S., & Tepe, J. J. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00489 · Cited by 100 · see citing works

Human High Temperature Requirement Serine Protease A1 (HTRA1) Degrades Tau Protein Aggregates

Tennstaedt, A., Poepsel, S., Truebestein, L., Hauske, P., Brockmann, A., Schmidt, N., Irle, I., Saccà, B., Niemeyer, C. M., Brandt, R., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.316232 · Cited by 98 · see citing works

Lithium and dementia: A preliminary study

Terao, T., Nakano, H., Inoue, Y., Okamoto, T., Nakamura, J., & Iwata, N. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.04.020 · Cited by 98 · see citing works

A farnesyltransferase inhibitor activates lysosomes and reduces tau pathology in mice with tauopathy

Hernández, I., Luna, G., Rauch, J. N., Reis, S. A., Giroux, M., Karch, C. M. M., Boctor, D., Sibih, Y., Storm, N. J., Díaz, A., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat3005 · Cited by 95 · see citing works

Does Lithium Therapy Protect Against the Onset of Dementia?

Dunn, N., Holmes, C., & Mullee, M. (2005) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000155068.23937.9b · Cited by 94 · see citing works

Lithium treatment and risk for dementia in adults with bipolar disorder: Population-based cohort study

Gerhard, T., Devanand, D. P., Huang, C., Crystal, S., & Olfson, M. (2015) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.154047 · Cited by 94 · see citing works

cGMP via PKG activates 26S proteasomes and enhances degradation of proteins, including ones that cause neurodegenerative diseases

VerPlank, J. J. S., Tyrkalska, S. D., Fleming, A., Rubinsztein, D. C., & Goldberg, A. L. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003277117 · Cited by 93 · see citing works

Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex

Schweiger, S., Matthes, F., Posey, K. L., Kickstein, E., Weber, S. S., Hettich, M. M., Pfurtscheller, S., Ehninger, D., Schneider, R., & Krauß, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-12974-4 · Cited by 92 · see citing works

Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: A pilot study

Sakurai, H., Hanyu, H., Sato, T., Kume, K., Hirao, K., Kanetaka, H., & Iwamoto, T. (2012) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1447-0594.2012.00866.x · Cited by 91 · see citing works

Cyanine Dye N744 Inhibits Tau Fibrillization by Blocking Filament Extension: Implications for the Treatment of Tauopathic Neurodegenerative Diseases

Necula, M., Chirita, C. N., & Kuret, J. (2005) · Biochemistry · doi:10.1021/bi050387o · Cited by 91 · see citing works

Recent developments of protein kinase inhibitors as potential AD therapeutics

Tell, V., & Hilgeroth, A. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00189 · Cited by 90 · see citing works

CIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer’s Disease

Shentu, Y.-P., Huo, Y., Feng, X.-L., Gilbert, J., Zhang, Q., Liuyang, Z.-Y., Wang, X.-L., Wang, G., Zhou, H., Wang, X.-C., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.009 · Cited by 90 · see citing works

SUMO and Alzheimer’s Disease

Lee, L., Sakurai, M., Matsuzaki, S., Arancio, O., & Fraser, P. E. (2013) · NeuroMolecular Medicine · doi:10.1007/s12017-013-8257-7 · Cited by 89 · see citing works

“Clicked” Sugar–Curcumin Conjugate: Modulator of Amyloid-β and Tau Peptide Aggregation at Ultralow Concentrations

Dolai, S., Shi, W., Corbo, C. P., Sun, C., Averick, S. E., Obeysekera, D., Farid, M., Alonso, A. D. C., Banerjee, P., & Raja, K. S. (2011) · ACS Chemical Neuroscience · doi:10.1021/cn200088r · Cited by 87 · see citing works

Long-term oral lithium treatment attenuates motor disturbance in tauopathy model mice: Implications of autophagy promotion

Shimada, K., Motoi, Y., Ishiguro, K., Kambe, T., Matsumoto, S., Itaya, M., Kunichika, M., Mori, H., Shinohara, A., Chiba, M., et al. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.050 · Cited by 87 · see citing works

Stabilizing the Hsp70-Tau Complex Promotes Turnover in Models of Tauopathy

Young, Z. T., Rauch, J. N., Assimon, V. A., Jinwal, U. K., Ahn, M., Li, X., Dunyak, B. M., Ahmad, A., Carlson, G. A., Srinivasan, S. R., et al. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.04.014 · Cited by 84 · see citing works

Design and synthesis of curcumin derivatives as tau and amyloid β dual aggregation inhibitors

Okuda, M., Hijikuro, I., Fujita, Y., Teruya, T., Kawakami, H., Takahashi, T., & Sugimoto, H. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.08.092 · Cited by 84 · see citing works

O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease

Ryan, P., Xu, M., Davey, A. K., Danon, J. J., Mellick, G. D., Kassiou, M., & Rudrawar, S. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00143 · Cited by 84 · see citing works

APOE-Mimetic Peptides Reduce Behavioral Deficits, Plaques and Tangles in Alzheimer’s Disease Transgenics

Vitek, M. P., Christensen, D. J., Wilcock, D. M., Davis, J., Nostrand, W. E. V., Li, F. Q., & Colton, C. A. (2012) · Neurodegenerative Diseases · doi:10.1159/000334914 · Cited by 82 · see citing works

Treatment of Alzheimer’s by PROTAC-Tau Protein Degradation

Kargbo, R. B. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00083 · Cited by 82 · see citing works

Natural products and their derivatives as multifunctional ligands against Alzheimer's disease

Patil, P., Thakur, A., Sharma, A., & Flora, S. J. S. (2019) · Drug Development Research · doi:10.1002/ddr.21587 · Cited by 81 · see citing works

Synthesis, Inhibitory Activity of Cholinesterases, and Neuroprotective Profile of Novel 1,8-Naphthyridine Derivatives

Rı́os, C. D. L., Egea, J., Marco, J. L., Leon, R. M., Samadi, A., Iriepa, I., Moraleda, I., Galvez‐Ruano, E., Garcı́a, A. G., López, M. G., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901902w · Cited by 79 · see citing works

Sulforaphane Upregulates the Heat Shock Protein Co‐Chaperone CHIP and Clears Amyloid‐β and Tau in a Mouse Model of Alzheimer's Disease

Lee, S., Choi, B., Kim, J., LaFerla, F. M., Park, J. H. Y., Han, J., Lee, K. W., & Kim, J. (2018) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201800240 · Cited by 79 · see citing works

Elevation of Global O-GlcNAc in Rodents Using a Selective O-GlcNAcase Inhibitor Does Not Cause Insulin Resistance or Perturb Glucohomeostasis

Macauley, M. S., Shan, X., Yuzwa, S. A., Gloster, T. M., & Vocadlo, D. J. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.07.005 · Cited by 78 · see citing works

Examining the Relationship between Trace Lithium in Drinking Water and the Rising Rates of Age-Adjusted Alzheimer’s Disease Mortality in Texas

Fajardo, V. A., Fajardo, V. A., LeBlanc, P. J., & MacPherson, R. E. K. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170744 · Cited by 78 · see citing works

Nanoparticle-mediated approaches for Alzheimer’s disease pathogenesis, diagnosis, and therapeutics

Hettiarachchi, S. D., Zhou, Y., Seven, E. S., Lakshmana, M. K., Kaushik, A. K., Chand, H. S., & Leblanc, R. M. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.034 · Cited by 77 · see citing works

Small Molecule Modulation of Proteasome Assembly

Njomen, E., Osmulski, P. A., Jones, C. L., Gaczynska, M. E., & Tepe, J. J. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00579 · Cited by 76 · see citing works

Curcumin intervention for cognitive function in different types of people: A systematic review and meta-analysis

Zhu, L., Mei, X., Zhang, Z., Xie, Y., & Lang, F. (2019) · Phytotherapy Research · doi:10.1002/ptr.6257 · Cited by 76 · see citing works

Sildenafil for the Treatment of Alzheimer’s Disease: A Systematic Review

Sanders, O. D. (2020) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-200166 · Cited by 76 · see citing works

Cilostazol Add-On Therapy in Patients with Mild Dementia Receiving Donepezil: A Retrospective Study

Ihara, M., Nishino, M., Taguchi, A., Yamamoto, Y., Hattori, Y., Saitô, S., Takahashi, Y., Tsuji, M., Kasahara, Y., Takata, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089516 · Cited by 75 · see citing works

A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer’s Disease

Malpas, C. B., Vivash, L. E., Genc, S., Saling, M. M., Desmond, P. M., Steward, C. E., Hicks, R. J., Callahan, J., Brodtmann, A. G., Collins, S. J., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160544 · Cited by 75 · see citing works

The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design

Ling, Y., Hao, Z., Liang, D., Zhang, C., Liu, Y., & Wang, Y. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s329547 · Cited by 428 · see citing works

Challenges and hopes for Alzheimer’s disease

Tatulian, S. A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.016 · Cited by 291 · see citing works

The SARS‐CoV‐2 main protease (M pro ): Structure, function, and emerging therapies for COVID‐19

Hu, Q., Xiong, Y., Zhu, G., Zhang, Y., Zhang, Y., Huang, P. C., & Ge, G. (2022) · MedComm · doi:10.1002/mco2.151 · Cited by 262 · see citing works

Dysfunctional Glucose Metabolism in Alzheimer’s Disease Onset and Potential Pharmacological Interventions

Kumar, V., Kim, S.-H., & Bishayee, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179540 · Cited by 115 · see citing works

Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer’s Disease and Identifying Promising Drug Targets

Fišar, Z. (2022) · Biomolecules · doi:10.3390/biom12111676 · Cited by 110 · see citing works

The therapeutic landscape of tauopathies: challenges and prospects

Cummings, J. L., González, M. I., Pritchard, M. C., May, P. C., Toledo, L. M., & Harris, G. A. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01321-7 · Cited by 80 · see citing works

Role of Tau Protein in Neurodegenerative Diseases and Development of Its Targeted Drugs: A Literature Review

Yang, J., Zhi, W., & Wang, L. (2024) · Molecules · doi:10.3390/molecules29122812 · Cited by 63 · see citing works

The Common Cellular Events in the Neurodegenerative Diseases and the Associated Role of Endoplasmic Reticulum Stress

Kim, S., Kim, D. K., Jeong, S., & Lee, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115894 · Cited by 67 · see citing works

Dietary Supplements and Natural Products: An Update on Their Clinical Effectiveness and Molecular Mechanisms of Action During Accelerated Biological Aging

Chen, Y., Hamidu, S., Yang, X., Yan, Y., Wang, Q., Li, L., Oduro, P. K., & Li, Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.880421 · Cited by 61 · see citing works

Neurodegeneration cell per cell

Balusu, S., Praschberger, R., Lauwers, E., Strooper, B. D., & Verstreken, P. (2023) · Neuron · doi:10.1016/j.neuron.2023.01.016 · Cited by 51 · see citing works

Hybrid Quinoline-Thiosemicarbazone Therapeutics as a New Treatment Opportunity for Alzheimer’s Disease‒Synthesis, In Vitro Cholinesterase Inhibitory Potential and Computational Modeling Analysis

Zaib, S., Munir, R., Younas, M. T., Kausar, N., Ibrar, A., Aqsa, S., Shahid, N., Asif, T. T., Alsaab, H. O., & Khan, I. A. (2021) · Molecules · doi:10.3390/molecules26216573 · Cited by 49 · see citing works

Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease

Aillaud, I., & Funke, S. A. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-022-01230-7 · Cited by 49 · see citing works

Novel inhibitors of AChE and Aβ aggregation with neuroprotective properties as lead compounds for the treatment of Alzheimer's disease

Liu, Y., Uras, G., Onuwaje, I., Li, W., Yao, H., Xu, S., Li, X., Li, X., Phillips, J. B., Allen, S., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114305 · Cited by 46 · see citing works

All Roads Lead to Rome: Different Molecular Players Converge to Common Toxic Pathways in Neurodegeneration

Argueti-Ostrovsky, S., Alfahel, L., Kahn, J., & Israelson, A. (2021) · Cells · doi:10.3390/cells10092438 · Cited by 45 · see citing works

Tau degradation in Alzheimer's disease: Mechanisms and therapeutic opportunities

Wang, L., Banesh, S., Kumar, R., Schedin‐Weiss, S., Tjernberg, L. O., & Winblad, B. G. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70048 · Cited by 45 · see citing works

Disrupting pathologic phase transitions in neurodegeneration

Hurtle, B. T., Xie, L., & Donnelly, C. J. (2023) · Journal of Clinical Investigation · doi:10.1172/jci168549 · Cited by 39 · see citing works

Tau Protein and Tauopathies: Exploring Tau Protein–Protein and Microtubule Interactions, Cross‐Interactions and Therapeutic Strategies

Lorenzo, D. D. (2024) · ChemMedChem · doi:10.1002/cmdc.202400180 · Cited by 40 · see citing works

Carbamate as a potential anti‐Alzheimer's pharmacophore: A review

Singh, Y. P., Kumar, N., Chauhan, B. S., & Garg, P. (2023) · Drug Development Research · doi:10.1002/ddr.22113 · Cited by 36 · see citing works

Microwave-Assisted Synthesis of (Piperidin-1-yl)quinolin-3-yl)methylene)hydrazinecarbothioamides as Potent Inhibitors of Cholinesterases: A Biochemical and In Silico Approach

Munir, R., Zia‐ur‐Rehman, M., Murtaza, S., Zaib, S., Javid, N., Awan, S. J., Iftikhar, K., Athar, M., & Khan, I. A. (2021) · Molecules · doi:10.3390/molecules26030656 · Cited by 31 · see citing works

Tau-Targeted Therapeutic Strategies: Mechanistic Targets, Clinical Pipelines, and Analysis of Failures

Shen, X., Li, H., Zhang, B., Li, Y., & Zhu, Z. (2025) · Cells · doi:10.3390/cells14191506 · Cited by 32 · see citing works

Pyridine and Pyrimidine hybrids as privileged scaffolds in antimalarial drug discovery: A recent development

Ravindar, L., Hasbullah, S. A., Rakesh, K. P., Raheem, S., Ismail, N., Ling, L. Y., & Hassan, N. I. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129992 · Cited by 28 · see citing works

Therapeutic Options in Alzheimer’s Disease: From Classic Acetylcholinesterase Inhibitors to Multi-Target Drugs with Pleiotropic Activity

Cacabelos, R., Martínez-Iglesias, O. A., Cacabelos, N., Carrera, I., Corzo, L., & Naidoo, V. (2024) · Life · doi:10.3390/life14121555 · Cited by 31 · see citing works

Thioxanthenone-based derivatives as multitarget therapeutic leads for Alzheimer's disease

Tonelli, M., Catto, M., Sabaté, R., Francesconi, V., Laurini, E., Pricl, S., Pisani, L., Miniero, D. V., Liuzzi, G. M., Gatta, E., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115169 · Cited by 26 · see citing works

Targeting of PP2 A/GSK3β/PTEN Axis in Alzheimer Disease: The Mooting Evidence, Divine, and Devil

Alqahtani, S. M., Al-Kuraishy, H. M., Al-Gareeb, A. I., Abdel‐Fattah, M. M., Alsaiari, A. A., Alruwaili, M., Papadakis, M., Alexiou, A. T., & Batiha, G. E. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01554-0 · Cited by 26 · see citing works

Current Status of Alzheimer’s Disease and Pathological Mechanisms Investigating the Therapeutic Molecular Targets

Bagga, S., & Kumar, M. (2022) · Current Molecular Medicine · doi:10.2174/1566524022666220404112843 · Cited by 25 · see citing works

Cyclic dipeptide‐based small molecules modulate zinc‐mediated liquid–liquid phase separation of tau

Ramesh, M., Balachandra, C., Baruah, P., & Govindaraju, T. (2022) · Journal of Peptide Science · doi:10.1002/psc.3465 · Cited by 24 · see citing works

Dual Drug Repurposing: The Example of Saracatinib

Ramos, R., & Vale, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084565 · Cited by 24 · see citing works

The innate immune response in tauopathies

Johnson, A. M., & Lukens, J. R. (2023) · European Journal of Immunology · doi:10.1002/eji.202250266 · Cited by 20 · see citing works

Artificial intelligence assisted identification of potential tau aggregation inhibitors: ligand- and structure-based virtual screening, in silico ADME, and molecular dynamics study

Das, B., Mathew, A. T., Baidya, A. T. K., Devi, B., Rampa, R. S., & Kumar, R. (2023) · Molecular Diversity · doi:10.1007/s11030-023-10645-3 · Cited by 19 · see citing works

Alzheimer’s Disease Pathology and Assistive Nanotheranostic Approaches for Its Therapeutic Interventions

Dey, A., Ghosh, S., Rajendran, R. L., Bhuniya, T., Das, P., Bhattacharjee, B., Das, S., Mahajan, A. A., Samant, A., Anand, K., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179690 · Cited by 19 · see citing works

Protein aggregation and neurodegenerative disease: Structural outlook for the novel therapeutics

Arar, S. H., Haque, M. A., & Kayed, R. (2023) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26561 · Cited by 19 · see citing works

New insights into the therapeutic approaches for the treatment of tauopathies

Singh, H., Das, A., Khan, M. M., & Pourmotabbed, T. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.385288 · Cited by 18 · see citing works

Decoupling phase separation and fibrillization preserves activity of biomolecular condensates

Mahendran, T. S., Singh, A. A., Srinivasan, S., Jennings, C. M., Neureuter, C., Gindra, B. H., Parekh, S. H., & Banerjee, P. R. (2026) · Nature Communications · doi:10.1038/s41467-026-69244-z · Cited by 18 · see citing works

Design, synthesis, in vitro, and in silico studies of 4-fluorocinnamaldehyde based thiosemicarbazones as urease inhibitors

Islam, M. F., Ullah, S. M., Khan, A., Batool, Z., Mali, S. N., Gurav, S. S., Dahlous, K. A., Mohammad, S., Hussain, J., Al-Harrasi, A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-024-83386-4 · Cited by 16 · see citing works

Synthesis and biological evaluation of 2-nitrocinnamaldehyde derived thiosemicarbazones as urease inhibitors

Islam, M. F., Khan, A., Khan, M., Halim, S. A., Ullah, S. M., Hussain, J., Al-Harrasi, A., Shafiq, Z., Tasleem, M., & El‐Gokha, A. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.135387 · Cited by 15 · see citing works

Therapies for Tau-associated neurodegenerative disorders: targeting molecules, synapses, and cells

Robbins, M. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.373670 · Cited by 14 · see citing works

Blocking tau transmission by biomimetic graphene nanoparticles

Zhu, R., Makwana, K. M., Zhang, Y., Rajewski, B. H., Valle, J. R. D., & Wang, Y. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb00850a · Cited by 14 · see citing works

Investigation of Potential Drug Targets Involved in Inflammation Contributing to Alzheimer’s Disease Progression

Sharo, C., Zhai, T., & Huang, Z. J. (2024) · Pharmaceuticals · doi:10.3390/ph17010137 · Cited by 13 · see citing works

Design and synthesis of phenoxy methyl‐oxadiazole compounds against Alzheimer's disease

Evren, A. E., Nuha, D., Özkan, B. N. S., Kahraman, Ç., Gönülalan, E. M., & Yurttaş, L. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400115 · Cited by 13 · see citing works

Emerging paradigms in Alzheimer's therapy

Agnes Preethy, H., Rajendran, K., Sukumar, A. J., & Krishnan, U. M. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176872 · Cited by 14 · see citing works

sp 2 -Iminosugars targeting human lysosomal β-hexosaminidase as pharmacological chaperone candidates for late-onset Tay-Sachs disease

González‐Cuesta, M., Herrera‐González, I., García‐Moreno, M. I., Ashmus, R. A., Vocadlo, D. J., Fernández, J. M. G., Nanba, E., Higaki, K., & Mellet, C. O. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2073444 · Cited by 13 · see citing works

Synthesis and biological evaluation of Halogen-Substituted novel α-Ketoamides as potential protein aggregation modulators in Alzheimer’s disease

Das, B., Baidya, A. T. K., Chakrabarti, S., Chouhan, D., Thakur, B., Darreh‐Shori, T., Chen, G., Tiwari, V. K., & Kumar, R. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107373 · Cited by 12 · see citing works

Role of Tau protein in long COVID and potential therapeutic targets

Marwaha, B. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1280600 · Cited by 11 · see citing works

Amylin and Secretases in the Pathology and Treatment of Alzheimer’s Disease

Singh, S. P., Yang, F., Sivils, A., Cegielski, V., & Chu, X. (2022) · Biomolecules · doi:10.3390/biom12070996 · Cited by 11 · see citing works

Dynamic-Inspired Perspective on the Molecular Inhibitor of Tau Aggregation by Glucose Gallates Based on Human Neurons

Hu, Y., Yang, D., Tu, Y., Chai, K., Chu, L., Shi, S., & Yao, T. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00554 · Cited by 11 · see citing works

New Approaches to the Treatment of Alzheimer’s Disease

Kruk-Słomka, M., Kuceł, D., Małysz, M., Machnikowska, A., Orzelska‐Górka, J., & Biała, G. (2025) · Pharmaceuticals · doi:10.3390/ph18081117 · Cited by 11 · see citing works

Systems biology of Alzheimer’s Disease: a scoping review of key pathways and mechanisms

Bice, P. J., Nho, K. T., Ertekin‐Taner, N., & Saykin, A. J. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00934-4 · Cited by 13 · see citing works

Exploring Chemistry with Pyridine Derivatives

Pal, S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100792 · Cited by 10 · see citing works

Structure-Guided Design of N-Methylpropargylamino-Quinazoline Derivatives as Multipotent Agents for the Treatment of Alzheimer’s Disease

Svobodová, B., Pulkrabkova, L., Panek, D., Misiachna, A., Kolcheva, M., Andrýs, R., Handl, J., Čapek, J., Nyvltová, P., Roušar, T., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119124 · Cited by 10 · see citing works

Targeting mitochondrial dysfunction in Alzheimer's disease: New findings and perspectives

Hroudová, J., & Fišar, Z. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111491 · Cited by 9 · see citing works

Tideglusib Ameliorates Ischemia/Reperfusion Damage by Inhibiting GSK-3β and Apoptosis in Rat Model of Ischemic Stroke

Joshi, B., Singh, D., Wasan, H., Sharma, U., & Reeta, K. H. (2022) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2022.106349 · Cited by 9 · see citing works

Recent advances and future therapy development for Alzheimer's disease and related disorders

Hong, M., & Bitan, G. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.391182 · Cited by 9 · see citing works

Diverse influences on tau aggregation and implications for disease progressionPreprint

Alstyne, M. V., Pratt, J., & Parker, R. (2025) · Genes & Development · doi:10.1101/gad.352551.124 · Cited by 10 · see citing works

Tau Liquid–Liquid Phase Separation in Alzheimer’s Disease: Mechanisms, Pathogenesis, and Therapeutic Implications

Tian, S., Liu, Y., Hong, H., & Li, S. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05280-y · Cited by 8 · see citing works

Microdissected Pyramidal Cell Proteomics of Alzheimer Brain Reveals Alterations in Creatine Kinase B-Type, 14-3-3-γ, and Heat Shock Cognate 71

Matton, A., Axenhus, M., Bogdanović, N., Winblad, B. G., Schedin‐Weiss, S., Nilsson, P., & Tjernberg, L. O. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.735334 · Cited by 8 · see citing works

Tauopathies: The Role of Tau in Cellular Crosstalk and Synaptic Dysfunctions

Caamaño-Moreno, M., & Gargini, R. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.02.034 · Cited by 7 · see citing works

β-Bracelets: Macrocyclic Cross-β Epitope Mimics Based on a Tau Conformational Strain

Rajewski, B. H., Makwana, K. M., Angera, I. J., Geremia, D. K., Zepeda, A. R., Hallinan, G. I., Vidal, R., Ghetti, B. F., Serrano, A. L., & Valle, J. R. D. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c06830 · Cited by 8 · see citing works

Functional Analysis of Direct In Vitro Effect of Phosphorylated Tau on Mitochondrial Respiration and Hydrogen Peroxide Production

Fišar, Z., & Hroudová, J. (2025) · Biomolecules · doi:10.3390/biom15040495 · Cited by 6 · see citing works

Synthesis and Potential Dual Inhibitory Activity Against Acetylcholinesterase and Butyrylcholinesterase of Galactose‐Conjugated Isatin β‐Thiosemicarbazones

Thành, N. Đ., Giang, N. T. K., Toán, V. N., Van, H. T. K., Tri, N. M., Anh, H. H., & Hai, D. S. (2023) · ChemistrySelect · doi:10.1002/slct.202301632 · Cited by 6 · see citing works

Multi‐Target‐Directed Ligands ( MTDLs ) as Potential Therapeutic Candidates Targeting Multiple Pathogenic Factor of Alzheimer's Disease

Jung, J., Kim, Y., Cirunduzi, A. C., Yoon, S., Bang, S., & Yang, S. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.70919 · Cited by 5 · see citing works

Hybrid/Chimera Drugs - Part 1 - Drug Hybrids Affecting Diseases of the Central Nervous System

Nudelman, A. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673305662240702071354 · Cited by 5 · see citing works

Polyoxometalates bind multiple targets involved in Alzheimer’s disease

Zaken, K. B., Bouhnik, R., Omer, N., Bloch, N., & Samson, A. O. (2025) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-025-02111-2 · Cited by 5 · see citing works

Targeted tau protein degradation: a promising therapeutic approach for tauopathies

Baazaoui, N., Alfaifi, M. Y., Shati, A. A., Saad, R. B., & Garzoli, S. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.11.041 · Cited by 4 · see citing works

Carbohydrate-Derived Polytriazole Nanoparticles Enhance the Anti-Inflammatory Activity of Cilostazol

Rivas, M. V., Musikant, D., Peña, R. D., Álvarez, D. S., Pelazzo, L., Rossi, E., Martínez, K. D., Errea, M. I., Pérez, O. E., Varela, O. J., et al. (2022) · ACS Omega · doi:10.1021/acsomega.2c02969 · Cited by 4 · see citing works

Small molecules to target tau amyloid aggregation

Manglano-Artuñedo, Z., Peña‐Díaz, S., & Ventura, S. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.380900 · Cited by 4 · see citing works

Metallic and polymeric green nanoplatforms in oncology

Jadhav, M., & Prabhu, A. (2022) · Journal of Applied Microbiology · doi:10.1093/jambio/lxac044 · Cited by 4 · see citing works

In silico and In vivo protective effect of biochanin-A mitigating doxorubicin- induced cognitive deficits and neuroinflammation: Insights to the role of p-Tau and miR-132

Hussein, S., Tolba, M. F., Michel, H. E., Albohy, A., & Azab, S. S. (2025) · NeuroToxicology · doi:10.1016/j.neuro.2025.01.003 · Cited by 3 · see citing works

Discovery of a new class of triazole based inhibitors of acetyl transferase KAT2A

Pacifico, R., Gaudio, N. D., Bove, G., Altucci, L., Siragusa, L., Cruciani, G., Ruvo, M., Bellavita, R., Grieco, P., & Adamo, M. F. A. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2097447 · Cited by 3 · see citing works

Repurposing FDA-Approved Drugs Against Potential Drug Targets Involved in Brain Inflammation Contributing to Alzheimer’s Disease

Sharo, C., Zhang, J., Zhai, T., Bao, J., Garcia-Epelboim, A. D., Mamourian, E., Shen, L., & Huang, Z. J. (2024) · Targets · doi:10.3390/targets2040025 · Cited by 3 · see citing works

Tau protein aggregation: A therapeutic target for neurodegenerative diseases

Duggal, A., Mahindru, D., Baghel, K., Mehrotra, S., & Prajapati, V. K. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2024.11.012 · Cited by 2 · see citing works

N-Heterocyclic Compounds, In silico Molecular Docking Studies, and In vitro Enzyme Inhibition Effect against Acetylcholinesterase Inhibitors

Güzel, A., Isık, Z., Gök, Y., Taşkın‐Tok, T., & Aktaş, A. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230614150520 · Cited by 2 · see citing works

Nano-Theranostics Approaches and Mitochondrial Targeted Drug Delivery: Alzheimer ’s Disease Therapeutic InterventionsPreprint

Chacko, L., Nag, S., Dewanjee, S., Ghosh, S., Vallamkondu, J., Mitra, O., Dey, A., Bhuniya, T., Paluru, H. P. R., Reddy, P. H., et al. (2022) · Preprints.org · doi:10.20944/preprints202211.0032.v1 · Cited by 2 · see citing works

Inhibition and Disassembly of Tau Aggregates by Engineered Graphene Quantum DotsPreprint

Zhu, R., Makwana, K. M., Zhang, Y., Rajewski, B. H., Valle, J. R. D., & Wang, Y. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.29.522245 · Cited by 2 · see citing works

Tau Amyloid Corona‐Shelled Nanoparticle‐Based Drug Screening Platform for Discovering Tau Oligomer‐Degrading Drugs

Jung, H. G., Park, D., Bang, J., Kim, Y. H., Jang, J. W., Kim, Y.-H., Kim, H., Lee, S., Moon, W., Hwang, K. S., et al. (2025) · Aggregate · doi:10.1002/agt2.70139 · Cited by 1 · see citing works

The Expanding Role of Pyridine Derivatives as Privileged Scaffolds in Cardiac Ionic Channels

Janapati, Y. K., Cheweti, S., Chidipi, B., Srinivas, M., & Junapudi, S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106759 · Cited by 1 · see citing works

Benzo[d]thiazol-5-yl Compounds as O-GlcNAcase Inhibitors for Treating Alzheimer’s Disease

Sabnis, R. W. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00259 · Cited by 1 · see citing works

NeuID, a novel neuron-specific lncRNA, resolves a key epigenetic mechanism linking gene silencing to Alzheimer’s diseasePreprint

Pradhan, R., Petrovic, Z., Sakib, M. S., Schröder, S., Krüger, D. M., Peña, T., Diniz, E., Burckhardt, S., Schütz, A., Grządzielewska, I., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.01.657217 · Cited by 1 · see citing works

CULTURE OF LEARNING AND PERFORMANCE GOALS IN THE UAE EDUCATION

Alkaabi, A. M. (2014) · ICERI proceedings

Curcumin Shows Neuroprotection against Oxidative Damage and Alters APP Processing Involving GSK-3β-mediated Protein O-GlcNAcylationPreprint

Wang, Z., Tao, P.-F., Sun, Y.-Y., Song, X., & Huang, H. (2023) · Research Square · doi:10.21203/rs.3.rs-2964826/v1

Exploring the staining potential of GSK-3 inhibitors in bovine teeth: a one-year laboratory investigation

Karacic, J., Eggmann, F., Weiger, R., & Zaugg, L. K. (2024) · SWISS DENTAL JOURNAL SSO – Science and Clinical Topics · doi:10.61872/sdj-2024-01-01

Polyphenol: Development of Polyphenol-Inspired Derivatives Targeting Pathological Factors of AD

Das, B., Baidya, A. T. K., & Kumar, R. (2023) · Springer eBooks · doi:10.1007/978-981-99-6038-5_10

Can an N-donor motif make a difference? Synthesis, physicochemical characterization, and biological activity of selected derivatives of rhodanine-3-acetic acid

Szłapa‐Kula, A., Kaźmierski, Ł., Biernasiuk, A., Latocha, M. T., Kuśmierz, D., Płonka-Czerw, J. M., Kałkus, M., Siębor, Z., Erfurt, K., Kula, S., et al. (2025) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2025.126991

Synthesis and biological evaluation of some pyrimidine derivatives as multifunctional ligands for the treatment of Alzheimer's disease

Öztürk, O., Oyardı, Ö., Sağkan, R. I., & Dündar, Y. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118445

AHA1 regulates Aβ production via modulation of APP expression and γ-secretase assemblyPreprint

Noorani, A. A., Islam, S., Catalfano, K. C., Wilkins, H., Blagg, B. S. J., Zou, K., & Wolfe, M. S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.03.686106

Signaling cascades of microtubule-associated protein Tau in Alzheimer’s disease

Velmurugan, G., Krishnan, D., Upadhyay, R., Sivasamy, R., Sevanan, M., & Chinnathambi, S. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.10.013

Saracatinib Promotes Hippocampal Myelin Regeneration and Oligodendrocyte Precursor Cell Maturation by Inhibiting the NOTCH1 Signaling Pathway in Epileptic Mice

Luo, X., Wu, W., Yu, B., Chen, S., Zhao, J., Min, J., & Gu, X. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04621-6

Additional file 1 of The therapeutic landscape of tauopathies: challenges and prospects

Cummings, J. L., González, M. I., Pritchard, M. C., May, P. C., Toledo‐Sherman, L., & Harris, G. A. (2024) · Figshare · doi:10.6084/m9.figshare.26623807

Biosimilars: Antibody and nanobody-based therapeutic approaches towards protein misfolding diseases

Chinnathambi, S., & Rangappa, N. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.10.014

Neuid: A Novel Neuron‐Enriched LncRNA that Connects Epigenetic Gene Silencing to Alzheimer's Disease

Pradhan, R., Petrovic, Z., Sakib, M. S., Schröder, S., Krüger, D. M., Peña, T., Diniz, E., Burkhardt, S., Schütz, A., Gisa, V., et al. (2026) · Advanced Science · doi:10.1002/advs.202514972 · Cited by 1 · see citing works

Using β-strand and β-hairpin peptidomimetics induced by constrained amino acids to modulate the aggregation of the microtubule associated protein Tau : design, synthesis and evaluation

Lorenzo, D. D. (2023) · theses.fr (ABES) · doi:10.70675/0bdac871z5f25z4b5az9467z96a6d16ffb34

AHA1 Regulates Aβ Production via Modulation of APP Abundance and γ‐Secretase Assembly

Noorani, A. A., Islam, S., Filip, E., Catalfano, K. C., Paswan, S. K., Nagarajan, V., Wilkins, H., Blagg, B. S. J., Zou, K., & Wolfe, M. S. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70544

BindingDB Entry 50017745: Novel inhibitors of AChE and Aβ aggregation with neuroprotective properties as lead compounds for the treatment of Alzheimer's disease.

BindingDB (2023) · UC San Diego · doi:10.7270/q26m3bx2

BindingDB Entry 50019577: Thioxanthenone-based derivatives as multitarget therapeutic leads for Alzheimer's disease.

BindingDB (2024) · UC San Diego · doi:10.7270/q2tt4w9n

Nanotheranostic Approach for Targeting Tauopathies in Alzheimer's Disease: Mechanistic Insight and Recent Advances

Sahu, K. K., Chaudhary, R., Farooqi, M. A., & Kaurav, M. (2024) · Drug Delivery Letters · doi:10.2174/0122103031331346241122152643 · Cited by 1 · see citing works

Development of tau-directed Small Molecule Modulators for Alzheimer’s Disease: a Recent Patent Review (2014–2018)

Lee, H. E., Lim, D., Lee, J. Y., Lim, S. M., & Pae, A. N. (2019) · Pharmaceutical Patent Analyst · doi:10.4155/ppa-2019-0003 · Cited by 11 · see citing works

Tau-Targeted Therapy in Alzheimer's Disease - History and Current State

Jurcău, A., & Nunkoo, V. S. (2021) · Frontiers in clinical drug research. Dementia · doi:10.2174/9789815039474121020004 · Cited by 6 · see citing works

Chapter 17. Tau-targeting Therapeutic Strategies for Alzheimer's Disease

Gopinath, P., Ramesh, M., & Govindaraju, T. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839162732-00487 · Cited by 3 · see citing works

Tau-Directed Therapies for Alzheimer’s Disease and Other Tauopathies

(2013) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781608057221113010006